Corrigendum to “Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations” [Eur J Cancer 207 (2024) 114158](S0959804924008141)(10.1016/j.ejca.2024.114158)
Kron A, Scheffler M, Wiesweg M, Hummel HD, Kulhavy J, Gatteloehner S, Kollmeier J, Schubart C, Groß T, Demes MC, Keymel S, Joosten M, Merkelbach-Bruse S, Woelwer CB, Tufman A, Kauffmann-Guerrero D, Oeser K, Zehaczek M, Jeratsch U, Wolf J (2024)
Publication Type: Journal article, Erratum
Publication year: 2024
Journal
Book Volume: 213
Article Number: 115074
DOI: 10.1016/j.ejca.2024.115074
Abstract
The authors removed the study acronym ‘RECAP’ throughout the article. The authors would like to add the following to acknowledgement section of the publication.
Authors with CRIS profile
Involved external institutions
Universitätsklinikum Köln
Germany (DE)
Universitätsklinikum Essen
Germany (DE)
Universitätsklinikum Würzburg
Germany (DE)
Universitätsklinikum Gießen und Marburg (UKGM)
Germany (DE)
HELIOS Kliniken
Germany (DE)
Eberhard Karls Universität Tübingen
Germany (DE)
Universitätsklinikum Frankfurt am Main (KGU)
Germany (DE)
Universitätsklinikum Düsseldorf
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Klinikum der Universität München
Germany (DE)
Novartis AG
Switzerland (CH)
Germany (DE)
Universitätsklinikum Essen
Germany (DE)
Universitätsklinikum Würzburg
Germany (DE)
Universitätsklinikum Gießen und Marburg (UKGM)
Germany (DE)
HELIOS Kliniken
Germany (DE)
Eberhard Karls Universität Tübingen
Germany (DE)
Universitätsklinikum Frankfurt am Main (KGU)
Germany (DE)
Universitätsklinikum Düsseldorf
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Klinikum der Universität München
Germany (DE)
Novartis AG
Switzerland (CH)
How to cite
APA:
Kron, A., Scheffler, M., Wiesweg, M., Hummel, H.D., Kulhavy, J., Gatteloehner, S.,... Wolf, J. (2024). Corrigendum to “Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations” [Eur J Cancer 207 (2024) 114158](S0959804924008141)(10.1016/j.ejca.2024.114158). European Journal of Cancer, 213. https://doi.org/10.1016/j.ejca.2024.115074
MLA:
Kron, Anna, et al. "Corrigendum to “Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations” [Eur J Cancer 207 (2024) 114158](S0959804924008141)(10.1016/j.ejca.2024.114158)." European Journal of Cancer 213 (2024).
BibTeX: Download